MYRISTOLEIC ACID manufacturers
- Myristoleic acid
-
- $58.00 / 25mg
-
2024-11-19
- CAS:544-64-9
- Min. Order:
- Purity: 99.65%
- Supply Ability: 10g
- MYRISTOLEIC ACID
-
- $9.00 / 1KG
-
2024-10-11
- CAS:544-64-9
- Min. Order: 1KG
- Purity: 99.8%
- Supply Ability: 100tons
- MYRISTOLEIC ACID
-
- $0.00 / 25kg
-
2024-04-12
- CAS:544-64-9
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000ton
|
| | MYRISTOLEIC ACID Basic information |
| Product Name: | MYRISTOLEIC ACID | | Synonyms: | DELTA 9 CIS TETRADECENOIC ACID;C14:1 (CIS-9) ACID;(Z)-tetradec-9-enoic acid;MYRISTOLEIC ACID 99%;9-Tetradecenoic acid, (9Z)-;(9Z)-9-Tetradecenoic acid;Myristolenic acid;9-cis-Tetradecenoic acid | | CAS: | 544-64-9 | | MF: | C14H26O2 | | MW: | 226.35 | | EINECS: | 208-876-8 | | Product Categories: | | | Mol File: | 544-64-9.mol |  |
| | MYRISTOLEIC ACID Chemical Properties |
| Melting point | −4.5-−4 °C(lit.) | | Boiling point | 144 °C0.6 mm Hg(lit.) | | density | 0.9 g/mL at 25 °C(lit.) | | refractive index | n20/D 1.4562(lit.) | | Fp | 62 °C | | storage temp. | -20°C | | solubility | Benzene (Slightly), Chloroform (Slightly), Methanol (Slightly) | | form | Liquid | | pka | 4.78±0.10(Predicted) | | color | Colourless | | biological source | plant | | LogP | 5.383 (est) | | EPA Substance Registry System | 9-Tetradecenoic acid, (9Z)- (544-64-9) |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | RIDADR | NA 1993 / PGIII | | WGK Germany | 3 |
| | MYRISTOLEIC ACID Usage And Synthesis |
| Chemical Properties | Colorless liquid. Found in fatof some seeds and in fish oil. | | Uses | Myristoleic Acid induces apoptosis and necrosis in human prostrate cancer cell LNCaP, and is of a potential for developing an attractive new tool for the treatment of prostrate cancer. | | Definition | ChEBI: Myristoleic acid is a tetradecenoic acid in which the double bond is at the 9-10 position and has Z configuration. Myristoleic acid has been isolated from Serenoa repens and has cytotoxic and apoptosis-inducing effects. It has a role as an apoptosis inducer, a plant metabolite and an EC 3.1.1.1 (carboxylesterase) inhibitor. It is a tetradecenoic acid and a long-chain fatty acid. It is a conjugate acid of a myristoleate. | | in vivo | Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice[2].
| Animal Model: | C57BL/6 mice at 5 weeks[2].
| | Dosage: | 0.2, 2 mg/kg | | Administration: | IP every 24 h for 4 days. | | Result: | Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B. Pm and ES/BS in a dose-dependent manner. |
| | IC 50 | Human Endogenous Metabolite |
| | MYRISTOLEIC ACID Preparation Products And Raw materials |
|